香港联交所最新资料显示，11月6日，瑞银增持中国同辐(01763)8.84万股，每股作价20.8565港元，总金 额约为184.37万港元。增持后最新持股数目约为400.49万股，最新持股比例为5.01%。 ...

智通财经APP获悉，香港联交所最新资料显示，11月6日，瑞银增持中国同辐(01763)8.84万股，每股作 价20.8565港元，总金额约为184.37万港元。增持后最新持股数目约为400.49万股，最新持股比例为 5.01%。 ...

每经AI快讯，中国同辐(01763.HK)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港 元，成交额1302.97万港元。 ...

消息面上，11月5日，诺华宣布其放射配体疗法（RLT）药物Pluvicto的两个适应症同时获得国家药监局 批准。据悉，Pluvicto为诺华旗下的一款核药爆品。平安证券指出，Pluvicto的获批有望进一步点燃国内 核医学行业热度，AD诊断核药有望随着治疗药物一同放量，建议关注国内在新核素和新靶点方面布局 领先的企业，比如中国同辐等。 值得注意的是，10月31日，中国同辐发布碳同位素产品，标志我国在稳定同位素领域高端技术突破"卡 脖子"难题，中国成为全球少数具备高丰度13CO气体和碳13尿素原料药生产能力的国家，公司成为完整 掌握呼气试验产品全产业链的龙头企业。同日，公司正式启动稳定同位素基地二期项目建设。 中国同辐(01763)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港元，成交额1302.97 万港元。 ...

消息面上，11月5日，诺华宣布其放射配体疗法(RLT)药物Pluvicto的两个适应症同时获得国家药监局批 准。据悉，Pluvicto为诺华旗下的一款核药爆品。平安证券指出，Pluvicto的获批有望进一步点燃国内核 医学行业热度，AD诊断核药有望随着治疗药物一同放量，建议关注国内在新核素和新靶点方面布局领 先的企业，比如中国同辐等。 值得注意的是，10月31日，中国同辐发布碳同位素产品，标志我国在稳定同位素领域高端技术突破"卡 脖子"难题，中国成为全球少数具备高丰度13CO气体和碳13尿素原料药生产能力的国家，公司成为完整 掌握呼气试验产品全产业链的龙头企业。同日，公司正式启动稳定同位素基地二期项目建设。 中国同辐(01763)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港元，成交额1302.97 万港元。 ...

Core Insights - As of November 10, a total of 108 stocks reached their 52-week highs, with notable performers including Taijin Holdings (08321), OKURA HOLDINGS (01655), and Hejia Holdings (00704) achieving high rates of 125.00%, 84.90%, and 53.57% respectively [1] Summary by Category 52-Week Highs - Taijin Holdings (08321) closed at 0.620 with a peak price of 0.900, marking a 125.00% increase - OKURA HOLDINGS (01655) reached a closing price of 0.280 and a high of 0.355, reflecting an 84.90% rise - Hejia Holdings (00704) had a closing price of 0.345 and a peak of 0.430, showing a 53.57% increase - Other notable stocks include Sanhe Chemical (00301) with a 41.67% increase and Aide New Energy (02623) with a 36.25% rise [1] 52-Week Lows - Wangshan Wangshui-B (02630) recorded a closing price of 52.850 and a low of 51.000, resulting in a -21.84% decrease - Eight Horses Tea (06980) had a closing price of 52.850 and a low of 51.100, reflecting a -10.98% decline - New Enjoy Times (08519) reached a low of 0.270, marking a -10.00% drop - Other significant declines include Jiujiang Bank (06190) at -8.99% and Kun Group (00924) at -6.98% [3][4]

Core Viewpoint - China Tongru (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the title of "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [13C/14C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the niche field of urea [13C] and [14C] breath diagnostics [1] - The urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers in China and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Dongfang (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Pharmaceutical Industry Single Champion" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - The company focuses on the application of medical isotopes in the niche market of Urea [13C] and [14C] breath diagnostics [1] - The Urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers domestically and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Tongru (01763.HK) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the urea [C] and [C] breath diagnostic niche, producing products used for detecting Helicobacter pylori [1] - The company's urea [C] and [C] breath test products cover over 20,000 end customers in China and are sold to 90 countries and regions, maintaining a leading market share in the industry for several consecutive years [1] Industry Summary - The company aims to further strengthen its position in technological innovation, continuously delve into breath diagnostics and related fields, and develop more advanced products and solutions to meet clinical needs, contributing to the health defense of the population [1]

本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻呼氣診斷產品榮獲國家級製藥業單項冠軍 本公司董事會（「董事會」）欣然宣佈，近日，中國同輻附屬公司深圳市中核海得威 生物科技有限公司憑藉核心產品「尿素[13C/14C]呼氣試驗藥盒」成功入選國家級製 造企業並榮獲「製藥業單項冠軍」。 中國同輻始終聚焦於醫用同位素應用中的尿素[13C]及[14C]呼氣診斷細分領域，生 產的尿素[13C]及[14C]呼氣試驗產品用於檢測幽門螺旋桿菌，產品覆蓋國內2萬餘 家終端客戶，銷往90個國家和地區，市場佔有率連續多年穩居行業前列。 中國同輻將進一步強化科技創新主體地位，持續深耕 ...